Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Dr. Percy H. Carter M.B.A., Ph.D.

Chief Scientific Officer

Ms. Tracey L. McCain Esq.

Executive Vice President, Chief Legal & Compliance Officer and Secretary

Mr. Alexis A. Borisy A.M.

Co-Founder & Director

Ms. Ariel  Hurley

Senior Vice President, Finance & Principal Accounting Officer

Dr. Christopher K. Murray Ph.D.

Chief Technical Operations & Quality Officer

Ms. Kathryn  Haviland

President, Chief Executive Officer & Director

Jenna  Cohen

Senior Director & Head of Investor Relations

Ms. Christina  Rossi M.B.A.

Chief Operating Officer

Mr. Michael  Landsittel

Chief Financial Officer

Dr. Fouad  Namouni M.D.

President of Research & Development

İsim	Piyasa değeri
Affimed N.V.	0M
Halozyme Therapeutics, Inc.	0M
Homology Medicines, Inc.	0M
Leafly Holdings, Inc.	0M
Walgreens Boots Alliance Inc	0M
Nektar Therapeutics	0M
Transgene SA	0M
Satudora Holdings Co.,Ltd.	0M
Camurus AB (publ)	0M
NEUCA S.A.	0M
Walgreens Boots Alliance, Inc.	0M

Blueprint Medicines Corporation

Blueprint Medicines Corporation Rakipler Listesi

Ana rakipler